stro-002
mAbexperimentalADC
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2019 (NCT03748186)
Timeline
Indications
Studied for
- Carcinoma, Endometrioid · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Ovarian Epithelial · Phase 2
- Endometrial Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lung Neoplasms · Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
Mechanism of action
- Folate receptor alphaINHIBITOR
FOLR1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- SC209
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095133 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06679582 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2024 | Innovative Therapies For Children with Cancer Consortium, National Cancer Institute (NCI), Sutro Biopharma |
| NCT06555263 | Phase 2 | Aug 21, 2024 | Sutro Biopharma |
| NCT06238687 | Phase 1/Phase 2 (Phase 2) | Nov 8, 2023 | Sutro Biopharma, Tasly Pharmaceuticals, Inc. |
| NCT05870748 | Phase 2 | Jul 12, 2023 | Gynecologic Oncology Group, Sutro Biopharma |
| NCT05200364 | Phase 1 | Mar 22, 2022 | Sutro Biopharma |
| NCT03748186 | Phase 1 | Feb 1, 2019 | Sutro Biopharma |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sutro Biopharma | For profit | 6 | 5 | 2 | 2019 |
| Gynecologic Oncology Group | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Innovative Therapies For Children with Cancer Consortium | Academic/Hospital | 1 | 0 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2024 |
| Tasly Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2023 |
5 organizations
Page 1 / 1